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Abstract:
Aim: The aim of present work was to develop microspheres of Famotidine using natural bioenhancers to 
achieve sustained action for treatment of Peptic ulcer.
Method: Ionotropic gelation method was used for the development of microspheres. During preliminary trials, 
optimum concentration of all the ingredients were selected through entrapment efficiency, dissolution studies 
method. An optimized formulation was prepared and evaluated for mean particle size, percentage buoyancy, 
dissolution studies, micromeritic studies. Microscopic characteristics of the optimized formulation were studied 
using Scanning electron microscopy. Stability studies and releae kinetics were studied for the optimized 
formulation.
Result: After preliminary trials, F5, F9, F11 and F13 were selected on the basis of entrapment efficiency and 
dissolution studies and their concentrations were utilised for preparing optimized formulation. Optimized 
Formulation of famotidine containing bio enhancers showed excellent floatability, good buoyancy, better 
micromeritics properties and increment in drug release. It was observed that release follows first order kinetics 
and good stability was observed for 2 months during stability studies.
Conclusion: Current results indicate a promising approach of Famotidine microspheres, as an alternative for 
treating Peptic ulcer.
Keywords: Famotidone, Bioenhancers, Dissolution studies, Microspheres, Peptic ulcer 
Corresponding author: 
Mr. Pankaj Verma, 
Department of Pharmacology, 
College of Pharmacy, PDM Group of Institution, 
Bahadurgarh, Harayana-124507, India
Tel: +91-9958453934
E-mail: Vermapankaj1614@gmail.com
Please cite this article in press as Pankaj Verma et al, Development and Optimisation of Polymeric 
Gastroretentive Microspheres of Famotidine with Natural Bioenhancers, Indo Am. J. P. Sci, 2017; 4(01).
QR code
IAJPS 2017, 4 (01), 137-148 Pankaj Verma et al ISSN 2349-7750
w w w . i a p s . c Page 138
INTRODUCTION:
Controlled release drug delivery systems provide a 
uniform drug concentration at the target tissue and 
thus after absorption allow maintenance of plasma 
concentration within a therapeutic range which 
reduces the frequency of administration and also 
minimizes side effects and may improve the 
therapy of peptic ulcer. Peptic ulcer is an upper 
gastrointestinal disorder occurring due to excessive 
acid and pepsin secretion from the parietal cells. 
Gastric ulcer occurs due to hydrolytic and 
proteolytic digestion of gastric mucosa. 
Furthermore, it has been evidenced that there lies 
an imbalance between aggressive factors like, 
pepsin, Non-steroidal Anti-inflammatory Drugs 
(NSAIDS), etc. and various protective factors like 
Prostaglandins (PG), mucus, bicarbonate and blood 
flow to mucosa. Inhibition of Prostaglandins
synthesis leads to decrease in mucus secretion 
which further protect gastric mucosa by acid and 
pepsin secretion leading to formation of gastric 
ulcers [8-13]. The multiple-unit (microspheres) 
floating drug delivery system has been designed to 
develop a reliable formulation which is devoid of 
all the disadvantages of single unit systems which 
includes release all or nothing during emptying 
process. On the other hand, multiple unit dosage 
system pass through Gastro-intestinal tract to avoid 
vagaries of gastric emptying and release the drug 
more uniformly leading to less local irritation, 
reduced intersubjective variability, low probability 
of dose dumping, site specific targeting increased 
absorption and bioavailability [1-7]. Bioavailabilty 
can be increased by adding bioenhancers, which 
themselves do not show typical drug activity but 
when used in combination with a drug molecule, 
they enhance its activity by increasing 
bioavailability or any other mechanism. They are 
also termed as absorption enhancers and act as 
functional excipients included in the formulation to 
increase absorption of drugs. Some examples are 
quercetin and kaempferol. Quercetin has shown to 
increase bioavailability, blood levels and efficacy 
of number of drugs including dilitiazem, digoxin 
and epigallocatechingallate. Dose dependent 
Kaempferol may also increase the bioavailability of 
etoposide [14][15]. The floating drug delivery 
system which results in delayed gastric emptying 
has several advantages. Drugs that have absorption 
window and also which is a reason for poor 
bioavailability can be delivered effectively. 
Treatment of all types of stomach and duodenal 
cancers can be done by buoyant formulation 
strategy. The floating strategy can also be 
beneficial in the development of various reflux 
formulations. Exploration of narrow spectrum 
antibodies using microspheres technique for the 
eradication of Helicobacter pylori was popularly 
accepted.
Therefore, the aim of this research work was to 
screen natural bio enhancers to enhance the activity 
of famotidine and develop microspheres for better 
gastro retention to achieve sustained action for the 
treatment of peptic ulcer, further optimized. 
MATERIALS AND METHODS:
Famotidine was obtained as a gift sample from 
Belco Pharmaceutical pvt. Ltd., Bahadurgarh, 
Harayana.  All the other raw materials were of 
analytical grade and of high purity, purchased from 
local source. Instruments were validated and 
laboratory conditions were well maintained 
throughout the entire procedure. 
Preformulation studies were done which involves 
solubility studies [16], physical compatibility as 
well as chemical compatibility studies [17]. The 
main excipients involved in preparation of 
microspheres include polymer, gas generating 
agent and bioenhancers. Sodium alginate was 
selected as polymer and calcium carbonate as a gas 
generating agent. However, the selection of 
bioenhancers is mainly done on the basis of their 
drug release enhancing property [18][19].  
Ionotropic gelation method was used for the 
formulation of microspheres. Famotidine (200mg) 
was accurately weighed and made solubilized in 
water and dispersed in a solution containing 
sodium alginate, calcium carbonate (gas forming 
agent), Quercetin and kaempferol. The resulting 
solution was dropped through a needle into 100 ml 
of solution containing calcium chloride (gelling 
agent) with acetone and glutaraldehyde. The beads 
were allowed to remain in the solution for half an 
hour to improve their mechanical strength. On 
expiration of this period the solution of gelling 
agent was decanted and beads were filtered and 
washed with deionized water. The beads were there 
after dried in hot air oven at a temperature of 60ºC. 
In preliminary trials, Formulations were formed 
with different excipients with varying 
concentrations. In formulation (F1-F5), varying 
concentrations of Sodium alginate were used with 
equiproportions of Calcium chloride (5%) and 
Famotidine (200 mg) as shown in Table 1. The 
effect of amount of Sodium Alginate on the 
entrapment efficiency and particle size of 
microspheres was evaluated [20].
IAJPS 2017, 4 (01), 137-148 Pankaj Verma et al ISSN 2349-7750
w w w . i a p s . c Page 139
Table 1: Amount of polymer (Sodium alginate) in Formulation (F1-F5)
Sodium alginate concentration(mg)
Calcium chloride 
(%)
Famotidine(mg)
F1(200) 5 200
F2(400) 5 200
F3(600) 5 200
F4(800) 5 200
F5(1000) 5 200
Table 2: Amount of various ingredients in formulation (F6-F13)
Ingredients Formulations
Calciumchloride 
(%)
Sodium 
alginate(gm)
Famotidine(mg)
Calcium carbonate : 
Sodium alginate
F6(0:1) 5 1 200
F7(0.5:1) 5 1 200
F8(0.75:1) 5 1 200
F9(1:1) 5 1 200
Quercetin (mg) F10(5) 5 1 200
F11(10) 5 1 200
Kaempferol (mg) F12(1) 5 1 200
F13(2) 5 1 200
In formulation (F6-F9), Calcium carbonate is 
mixed with sodium alginate at different ratios as 
shown in Table 2. A ‘bio enhancer’ is an agent 
which enhances the bioavailability and bio efficacy 
of a drug with which it is combined without any 
pharmacological activity of its own at the dose used 
such as Quercetin and Kaempferol. Quercetin has 
shown to increase bioavailability, blood levels and 
efficacy of number of drugs including dilitiazem, 
digoxin and epigallocatechingallate. Dose 
dependent Kaempferol may also increase the 
bioavailability of etoposide. In formulation (F10-
F11), quercetin was added with 5 mg as well as 10 
mg. Dose dependent Kaempferol may also increase 
the bioavailability of etoposide.  In formulation 
(F12-F13), kaemferol was added at concentrations 
of 1 mg and 2 mg, as shown in Table 2. In all these 
formulations, equiproportions of Calcium chloride 
(5%) and famotidine (200 mg) were also added 
[21].  
Evaluation of formulation trials 
Evaluation of formulation trials were done by 
determining mean particle size [22], Entrapment 
efficiency [23][24], as well as Dissolution studies 
[25]. The particle size of bio enhancers loaded 
famotidine microspheres was measured by optical 
microscope and the mean size of particles was 
calculated using a calibrated ocular micrometer. To 
determine the entrapment efficiency 25 mg of 
microspheres were weighed and thoroughly 
triturated and dissolved in 25 ml of 0.1N HCL. 
This mixture was centrifuged at 4200 rpm for 30 
minutes, filtered and analyzed 
spectrophotometrically 265nm against buffer as 
blank. The in-vitro release studies of drug loaded 
microspheres were carried out at 37ºC using pH 1.2 
0.1 N HCL. Using Dialysis Sac method, 25 mg of 
microspheres were weighed and added to conical 
flask containing 50 ml of 0.1N HCL and kept on a 
magnetic stirrer at 50rpm. The samples were 
withdrawn at regular time intervals for 12hrs from 
the dissolution medium and analyzed at 265nm by 
using UV-spectrophotometer. 
Preparation and Characterization of optimized 
formulation
From the above preliminary trials, optimum 
concentrations of all the excipients were selected 
and used for preparing an optimum formulation. 
After preparation of optimized formulation, 
characterization or evaluation of optimized 
formulation was done through various parameters.
Mean particle size: The particle size of bio 
enhancers loaded famotidine microspheres was 
measured by optical microscope and the mean size 
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of particles was calculated using a calibrated ocular 
micrometer [25][26]. 
Percentage buoyancy 
The floating test was carried out to investigate the 
floatability of famotidine microspheres. To access 
the floating properties, few milligrams of 
microspheres were placed in 0.1N HCL containing 
0.02% Tween 80 surfactant to simulate gastric
conditions. The mixture was stirred at 100 rpm on a 
magnetic stirrer. After 12 hours, the layer of 
buoyant microspheres was pipetted out and 
separated by filtration. Particles in the sinking 
particulate layer were separated by filtration. 
Particles of both the types were dried in hot air 
oven at 65 until constant weight. Both the fractions 
of microspheres were weighed and buoyancy was 
determined by the weight ratio of floating particles 
to the sum of floating and sinking particles. Despite 
the solution being stirred for 12h, the hollow 
microspheres still floated indicating that the 
microspheres exhibit an excellent buoyancy effect 
[24][25]. 
Micromeritic properties
The microspheres were characterized by their 
micromeritic properties such as \particle size,
tapped density, compressibility index, true density 
and flow property [26][27][28][29]. 
Dissolution studies 
The in-vitro release studies of drug loaded 
microspheres were carried out at 37ºC using pH 1.2 
0.1 N HCL. Using Dialysis Sac method, 25 mg of 
microspheres were weighed and added to conical 
flask containing 50 ml of 0.1N HCL and kept on a 
magnetic stirrer at 50rpm. The samples were 
withdrawn at regular time intervals for 12hrs from 
the dissolution medium and analyzed at 265nm by 
using UV-spectrophotometer. Equal volume of the 
dissolution medium was replaced in the vessel after 
each withdrawal to maintain sink conditions [26]. 
Scanning Electron Microscopy
The shape and surface characteristics of the 
optimized formulation was determined by Scanning 
electron microscope. Samples of microspheres 
were dusted onto a double adhesive tape. 
Afterwards the stub containing the sample was 
coated with gold using a cool sputter coater 
(Polaron SC 7640) to neutralize electrons and to 
obtain a clear morphology of the microspheres. 
Photomicrographs were taken at an accelerated 
voltage of 20Kv and chamber pressure of 0.6mm 
Hg [30]. 
Release kinetics 
To analyze the mechanism of drug release and 
release rate kinetics from the dosage form, the data 
obtained were fitted to Zero order, First order, 
Higuchi release and Korsmeyer- Peppas release 
model as shown in Table 3 [31][32].
Table 3: Drug release mechanisms
Drug transport
Release exponent 
(n)
Drug transport 
mechanism
0.45 Fickian diffusion
0.45<n<0.89 Anamolous transport
0.89 Case-II transport
Higher than 0.89 Super case- II transport
Stability studies
Optimized (Fopt) formulation was stored at 
different temperatures for 2 months. Then the 
colour, physical stability and concentration of 
famotidine were investigated. For the estimation of 
drug content, UV spectrophotometer is used. 
Accelerated studies were done by subjecting 
samples to 25±2ºC/65±5%RH and 
40±2ºC/75±5%RH respectively for 2 months. At 
the end of 0, 7, 15, 30 & 60 days samples were 
withdrawn and diluted with 0.1N HCL and 
analyzed with UV spectrophotometer [26][33]. 
RESULTS:
The solubility study of the drug was carried in 
various different solvents using “Shake flask 
method. The solubility of famotidine was 
determined as 2.38 g/ml in water and 29.71 g/ml in 
0.1 N HCL. There was no change observed in 
physical characteristics of samples containing drug, 
alone and in combination with sodium alginate in 
any ratio during the study when exposed to 
40oC/75%RH and 25oC/60% RH (i.e. normal and 
accelerated conditions as per ICH guidelines). 
Therefore, the excipients were considered suitable 
on preliminary basis.
From the DSC thermogram of physical mixture of 
drug and excipients, peaks corresponding to the 
melting endotherm of pure famotidine were shown 
in Figure 1. There was no significant change in the 
melting point of the drug when compared against 
pure drug as well as there was no appreciable peak 
observed. This indicated that there is no interaction 
between the drug and the excipients. In other 
words, drug and excipients were said to be 
compatible.
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Fig 1: DSC thermogram of drug and excipients
The FT-IR spectra of optimized formulation is 
given in figure 2. No appreciable change was 
observed in peaks of famotidine spectra in 
comparison to spectra of famotidine loaded 
microspheres. Therefore it can be concluded that no 
chemical interaction has occurred between the drug 
and excipients.
A
B
Fig 2: A: FTIR spectra of formulation B: FTIR spectra of famotidine
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Evaluation of formulation trials
Amount of sodium alginate significantly affects the 
particle size and entrapment efficiency of 
famotidine microspheres. The particle size was 
found to be increased when concentration of 
polymer was increased from F1 to F5 as shown in 
Table 4. 
Amount of calcium carbonate significantly affects 
the entrapment efficiency of famotidine 
microspheres. On increasing the concentration 
0:1(F6) (drug: polymer ratio) to 1:1(F9), it was 
noticed that entrapment efficiency decreases with 
its increasing concentration. On increasing the 
amount of calcium carbonate, it was found that 
microspheres floated for 24 hrs as shown in Table 
5. 
On increasing the amount of quercetin from 5mg 
(F10) to 10 mg (F11), it was found the drug release 
further increased at the end of 8 hrs. The values are 
given in Table 6, which indicates the increment in 
drug release by increasing the amount of quercetin.
Table 4: Entrapment efficiency and particle size of microspheres
S. no.
Sodium alginate 
concentration (mg)
Entrapment 
efficiency (%)
Average Particle size (µm)
1 F1(200) 38.5 706±1.23
2 F2(400) 46 773±1.45
3 F3(600) 53.5 813±1.28
4 F4(800) 59.5 879±1.83
5 F5(1000) 62.5 906±1.28
Table 5: Decrease in entrapment efficiency on increasing calcium carbonate
S. no. Calcium carbonate: Na alginate(mg)
Entrapment 
efficiency (%)
Floating ability(h)
1 F6(0:1) 64 ---
2 F7 (0.5:1) 62.5 24
3 F8(0.75:1) 57.2 24
4 F9(1:1) 55 24
Table No. 6: in-vitro dissolution profiles of Quercetin
Time(hrs) 5mg(F10) 10mg(F11)
1 14.23±0.11 17.12±0.17
2 15.19±0.13 18.43±0.16
3 15.82±0.04 18.92±0.14
4 17.80±0.07 24.16±0.09
5 18.18±0.08 28.52±0.07
6 21.96±0.09 29.89±0.08
7 24.85±0.12 31.29±0.11
8 27.70±0.02 34.51±0.12
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It was found that as the concentration of 
kaempferol increased from 1mg (F12) to 2mg 
(F13) drug release from famotidine microspheres 
also increased as shown in Table 7.
Preparation and Characterization of optimized 
batch 
Following concentrations of polymer and 
excipients were taken for preparing the best batch 
(Fopt) of famotidine microspheres with higher 
entrapment efficiency and higher drug release 
based on the preliminary trials data as shown in 
Table 8.
Mean particle size: Microspheres were prepared 
with optimized parameters and particle size was 
calculated using optical microscopy and particle 
diameter of 50 particles was measured as shown in 
Table 9. 
Percentage buoyancy: The optimized batch of 
microsphere was evaluated for percentage 
buoyancy effect. The microspheres remained 
buoyant for more than 12 hrs as shown in Table 9. 
Micromeritic properties: Microspheres were 
prepared with optimized parameters and evaluated 
for micromeritic properties like angle of repose, 
compressibility index, tapped density and bulk 
density as shown in Table 9.
Table 7: In-vitro dissolution profiles of Kaempferol 
Time (hrs) Kaempferol concentration
1mg(F12) 2mg(F13)
1 14.70±0.07 15.23±0.12
2 14.96±0.11 15.59±0.23
3 15.30±0.10 16.19±0.32
4 15.95±0.08 16.52±0.22
5 16.25±0.20 16.70±0.41
6 16.65±0.30 16.91±0.35
Table 8: List of ingredients
Quercetin 10mg
Kaempferol 2mg
Famotidine 200mg
Sodium alginate 1000mg
Calcium carbonate 500mg
Calcium chloride 5%
Table 9: Characterization of optimized formulation
Mean Particle Size Average particle size 906µm
Percentage buoyancy Weight of floating particles 0.091g
Weight of total particles 0.024g
Percentage buoyancy 79%
Micromeritic properties of the drug loaded hollow 
microspheres
Angle of repose (degree) 22.43º
Compressibility index I (%) 12
Tapped Density (g/cm3) 0.15
Bulk Density (g/cm3) 0.1333
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Dissolution studies: Cumulative drug release 
profile of Famotidine microspheres was calculated 
by using pharmacokinetic parameters shown in 
Table 10. It can be seen that drug release rate of 
batch containing no bio enhancers (control 
formulation) was less by 2 times as compared to 
the microspheres batch with quercetin and 
kaempferol (optimized batch) as seen in Figure 3. 
As a result, there is some improvement in drug 
release and floating was also satisfactory.
Scanning Electron Microscopy 
The morphology of microspheres was examined by 
scanning electron microscope using Zeiss EVO40. 
The view of the microspheres showed a fairly 
spherical structure with a rough surface 
morphology. The surface roughness may be due to 
incorporation of drug. The shell of the microsphere 
also showed some porous structure due to 
incorporation of calcium carbonate which is 
favorable for floating properties. 
Table 10: Cumulative drug release profile of famotidine microspheres
Fig 3: Comparative dissolution profile of Foptimized and control preparation
Time (hrs) %Drug release
1 15.50±2.89
2 16.24±2.76
3 16.30±2.45
4 17.00±2.23
5 20.00±2.13
6 22.00±1.14
7 25.00±1.11
8 27.80±1.44
9 34.50±1.46
10 42.80±0.92
11 52.00±0.87
12 60.40±0.86
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Fig 4: SEM image of optimized formulation
Kinetic Modelling
The in vitro release data obtained were fitted in to 
various kinetic equations. Correlation coefficients 
of individual batch with applied equation were 
given in Table 3. The value of R2 was more in first 
order drug release as shown in Table 11. The value 
on n is 0.45<n<0.89 that is non ficckian diffusion. 
Stability studies
The stability of famotidine microspheres 
formulations were evaluated at different conditions 
of room temperature (25±2°C) and under 
accelerated condition (40±2°C/75±5% RH). These 
were evaluated at regular intervals for 2 months. 
The results of stability studies showed that no 
change in physical appearance has occurred up to 2 
months at all temperature conditions. After 2 
months storage period, entrapment efficiency of 
microspheres was found to be 61.76±1.46 and 
61.88±1.50 at room and accelerated temperature 
respectively. The drug content was found to be 
maximum at room temperature (Table 12). It was 
found that no remarkable change occurred in the 
entrapment efficiency and drug content of the 
microspheres. The change in drug content observed 
at accelerated storage condition was plotted against 
time using software. 
Table 11: Correlation Coefficients of drug release curves
Zero order First order Higuchi Korsmeyer-peppas
R2 R2 R2 R2
0.8582 0.9458 0.8597 0.7240
Table 12: Accelerated analysis for chemical stability
CHEMICAL CHANGES
25±2/60%RH 40±2ºC/75%RH
%EE±SD %drug %EE±SD %drug
Content Content
0 62.50±1.20 100±0.90 62.5±1.09 100.90±0.3
7 62.20±0.92 99.80±0.23 62.16±1.20 99.79±0.43
15 62.16±1.44 99.79±0.41 62.08±1.45 99.77±0.26
30 62.04±1.38 99.76±0.35 62.00±1.43 99.75±0.41
60 61.76±1.46 99.69±0.45 62.88±1.50 99.58±0.49
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DISCUSSION:
Oral controlled drug delivery has become a 
promising approach for those drugs having shorter 
half- life and high dosing frequency. It also reduces 
fluctuations in drug plasma concentration. The 
physical properties of the drug delivery system 
{density and size} as well as the contents and food 
in the stomach governs the in-vivo performance of 
a dosage form. To provide good floating behavior 
in the stomach the density of the formulation 
should be less than the stomach contents. Floating 
drug delivery systems are the systems which float 
or remain buoyant in the stomach for a longer 
duration of time and release drug at the target area 
which enhances bioavailability. These forms are 
expected to remain buoyant in gastric fluids for 3-4 
hours without being effected by intrinsic rate of 
gastric emptying. The reasons of buoyancy are i) 
their low density as compared to gastric contents ii) 
formation of gaseous phase inside the stomach. 
PUD or peptic ulcer disease, is an ulcer (defined as 
mucosal erosions equal to or greater than 0.5 cm) 
of an area of GIT that is exposed to acid in 
sufficient concentrations. The extent of the drug 
absorption in a segment of the GIT depends on the 
rate of absorption as well as on the exposed surface 
area and time available for the drug absorption. It is 
well documented that the stomach may be used as a 
depot for the controlled release dosage forms. It is 
widely used in the management of peptic ulcer, 
duodenal ulcer, gastric esophagitis, Zollinger-
ellinson syndrome, etc. It has greater potency to 
eradicate H. pylori. 
A ‘bio enhancer’ is an agent which enhances the 
bioavailability and bio efficacy of a drug with 
which it is combined without any pharmacological 
activity of its own at the dose used. They reduce 
the dose, cost, and minimize drug toxicity and 
adverse reactions. Some examples are quercetin 
and kaempferol. Quercetin has shown to increase 
bioavailability, blood levels and efficacy of number 
of drugs including dilitiazem, digoxin and 
epigallocatechingallate. Dose dependent 
Kaempferol may also increase the bioavailability of 
etoposide. The multiple-unit floating drug delivery 
system has been designed to avoid vagaries of 
gastric emptying and release the drug more 
uniformly leading to less local irritation, reduced 
inter subject variability ,low probability of dose 
dumping. 
Ionic Gelation method was used in the preparation 
of floating microspheres of famotidine containing 
bio enhancers and it is the most common method to 
prepare alginate microspheres is to combine 
alginate with divalent ions.It was observed that 
amount of sodium alginate significantly affects the 
particle size and entrapment efficiency of 
famotidine microspheres. On increasing the amount 
of alginate from 200mg to 1000mg affected the 
entrapment efficiency. When the amount of 
alginate was 200mg, entrapment efficiency was 
found to be lower than that found in higher 
concentration of alginate that is 1000mg. The 
particle size was found to be increased when 
concentration of polymer was increased from 
200mg to 1000mg. It was found that on increasing 
the amount of calcium carbonate (gas generating 
agent) with polymer in the preparation of 
microspheres it was found that entrapment 
efficiency decreases with increase in concentration 
of calcium carbonate. On increasing the 
concentration of calcium carbonate from 0.25:1 
(drug: polymer ratio) to 2:1 it was noticed that 
entrapment efficiency decreases with its increasing 
concentration. 
Floating ability of microspheres was also affected 
by the concentration of calcium carbonate. On 
increasing the amount of calcium carbonate it was 
found that microspheres floated for 24 hrs. It was 
seen that the amount of quercetin mainly affects the 
release profile of famotidine microspheres. On 
adding quercetin 5mg drug release from famotidine 
microspheres was higher as compared to the 
quercetin free microspheres. On increasing the 
amount of quercetin from 5mg to 10 mg it was 
found the drug release further increased at the end 
of 8 hrs. So 10 mg of quercetin was selected for 
optimal drug release. The amount of kaempferol 
also affects the drug release profile of famotidine 
microspheres. On adding 1 mg of kaempferol in the 
preparation of famotidine microspheres it was 
found that drug release was more as compared to 
the famotidine microspheres containing no 
kaempferol. Further it was found that as the 
concentration of kaempferol increased from 1mg to 
2mg drug release from famotidine microspheres 
also increased. 
The angle of repose value was found to be 22.43º 
indicating potential flow of microspheres. These 
results were further potentiated by I value 12%. 
The density values were obviously less than that of 
gastric fluid implying that these microspheres will 
possess a great buoyancy effect in vivo.  It was 
noticed that drug release rate of batch containing no 
bio enhancers (control formulation) was less by 0.5 
times as compared to the microspheres batch with 
quercetin and kaempferol (optimized batch). As a 
result there is some improvement in drug release 
and floating was also satisfactory. The morphology 
of microspheres was examined by scanning 
electron microscope using Zeiss EVO40. The view 
of the microspheres showed a fairly spherical 
structure with a rough surface morphology. The 
surface roughness may be due to incorporation of 
drug. The shell of the microsphere also showed 
some porous structure due to incorporation of 
calcium carbonate which is favorable for floating 
properties.  The in-vitro release data obtained were 
fitted in to various kinetic equations. The value of 
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R2 was more in first order drug release. The value 
on n is 0.45<n<0.89 that is non ficckian diffusion. 
The stability of famotidine microspheres 
formulation were evaluated at different conditions 
of room temperature (25±2°C) and under 
accelerated condition (40±2°C/75±5% RH). It was 
found that no remarkable change occurred in the 
entrapment efficiency and drug content of the 
microspheres. 
CONCLUSION:
The microspheres prepared by ionic gelation 
method and with natural bio enhancers had lower 
densities, greater floatability for over 24 hours and 
retained in the gastric environment for a longer 
period of time. Famotidine is having a less 
bioavailability due to poor absorption and drug 
release, so as to increase the release profile of drug 
natural bio enhancers were used. Gastric retention 
time of drug was also increased as the microspheres 
floated for a period of 24 hours in body. The 
present study demonstrated that the hollow 
microspheres showed satisfactory drug entrapment 
efficiency, particle size and floating ability on 
appropriate balance between polymer and calcium 
carbonate. It also showed the invitro drug release 
increased by 0.5 times by appropriate concentration 
of bio enhancers (quercetin and kaempferol). In-
vitro obtained for the floating microspheres of 
famotidine containing bio enhancers showed 
excellent floatability, good buoyancy and 
increment in drug release. Thus major advantages 
of the system include ease of preparation, good 
buoyancy, high entrapment efficiency, increased 
in-vitro drug release.
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